25 XP   0   0   10

Altimmune Inc
Buy, Hold or Sell?

Let's analyse Altimmune together

PenkeI guess you are interested in Altimmune Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Altimmune Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Altimmune Inc

I send you an email if I find something interesting about Altimmune Inc.

Quick analysis of Altimmune (30 sec.)










What can you expect buying and holding a share of Altimmune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.5%

What is your share worth?

Current worth
$2.74
Expected worth in 1 year
$2.86
How sure are you?
55.0%

+ What do you gain per year?

Total Gains per Share
$0.12
Return On Investment
1.8%

For what price can you sell your share?

Current Price per Share
$6.89
Expected price per share
$3.42 - $14.84
How sure are you?
50%

1. Valuation of Altimmune (5 min.)




Live pricePrice per Share (EOD)

$6.89

Intrinsic Value Per Share

$-10.13 - $-3.80

Total Value Per Share

$-7.39 - $-1.06

2. Growth of Altimmune (5 min.)




Is Altimmune growing?

Current yearPrevious yearGrowGrow %
How rich?$194m$192.4m-$22.4m-13.2%

How much money is Altimmune making?

Current yearPrevious yearGrowGrow %
Making money-$21.6m-$20.7m-$960.5k-4.4%
Net Profit Margin-111,621.5%-366,413.3%--

How much money comes from the company's main activities?

3. Financial Health of Altimmune (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#261 / 1016

Most Revenue
#631 / 1016

Most Profit
#709 / 1016

Most Efficient
#999 / 1016

What can you expect buying and holding a share of Altimmune? (5 min.)

Welcome investor! Altimmune's management wants to use your money to grow the business. In return you get a share of Altimmune.

What can you expect buying and holding a share of Altimmune?

First you should know what it really means to hold a share of Altimmune. And how you can make/lose money.

Speculation

The Price per Share of Altimmune is $6.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Altimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Altimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.74. Based on the TTM, the Book Value Change Per Share is $0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Altimmune.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.45-6.5%-0.31-4.5%-0.30-4.3%-0.24-3.5%-0.09-1.3%
Usd Book Value Change Per Share0.628.9%0.030.5%-0.05-0.7%0.101.5%0.071.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%22.64328.6%11.46166.3%
Usd Total Gains Per Share0.628.9%0.030.5%-0.05-0.7%22.74330.1%11.53167.3%
Usd Price Per Share11.25-5.40-11.75-8.03-10.60-
Price to Earnings Ratio-6.30--4.04--9.74--9.68--45.50-
Price-to-Total Gains Ratio18.25--3,478.20-20.68--701.73--232.35-
Price to Book Ratio4.11-2.15-4.33-3.81-26.77-
Price-to-Total Gains Ratio18.25--3,478.20-20.68--701.73--232.35-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.89
Number of shares145
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.0022.64
Usd Book Value Change Per Share0.030.10
Usd Total Gains Per Share0.0322.74
Gains per Quarter (145 shares)4.503,297.43
Gains per Year (145 shares)18.0113,189.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10188131306013180
2036262626011926370
3054443939017939560
4072625252023952750
5090806565129865940
60108987878135879130
701261169191141792320
80144134105041477105510
90162152118171537118700
100180170131301596131890

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%4.036.00.010.0%12.062.00.016.2%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.011.01.040.0%18.020.02.045.0%30.041.03.040.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%3.00.017.015.0%5.00.035.012.5%6.00.068.08.1%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%10.010.00.050.0%22.018.00.055.0%34.039.01.045.9%

Fundamentals of Altimmune

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Fundamental data was last updated by Penke on 2024-04-11 00:18:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Altimmune Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Altimmune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Net Profit Margin of -85,516.2% means that $-855.16 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Altimmune Inc:

  • The MRQ is -85,516.2%. The company is making a huge loss. -2
  • The TTM is -111,621.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-85,516.2%TTM-111,621.5%+26,105.3%
TTM-111,621.5%YOY-366,413.3%+254,791.8%
TTM-111,621.5%5Y-98,054.0%-13,567.5%
5Y-98,054.0%10Y-50,248.2%-47,805.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-85,516.2%-197.2%-85,319.0%
TTM-111,621.5%-210.4%-111,411.1%
YOY-366,413.3%-279.3%-366,134.0%
5Y-98,054.0%-436.8%-97,617.2%
10Y-50,248.2%-599.3%-49,648.9%
1.1.2. Return on Assets

Shows how efficient Altimmune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -15.0% Return on Assets means that Altimmune generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Altimmune Inc:

  • The MRQ is -15.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.0%TTM-11.5%-3.5%
TTM-11.5%YOY-9.8%-1.7%
TTM-11.5%5Y-11.9%+0.4%
5Y-11.9%10Y-8.0%-3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.0%-13.6%-1.4%
TTM-11.5%-12.9%+1.4%
YOY-9.8%-11.9%+2.1%
5Y-11.9%-14.2%+2.3%
10Y-8.0%-16.2%+8.2%
1.1.3. Return on Equity

Shows how efficient Altimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -16.3% Return on Equity means Altimmune generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Altimmune Inc:

  • The MRQ is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-12.6%-3.7%
TTM-12.6%YOY-10.8%-1.9%
TTM-12.6%5Y-13.5%+0.8%
5Y-13.5%10Y-1.4%-12.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-17.0%+0.7%
TTM-12.6%-16.1%+3.5%
YOY-10.8%-15.4%+4.6%
5Y-13.5%-20.0%+6.5%
10Y-1.4%-21.1%+19.7%

1.2. Operating Efficiency of Altimmune Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Altimmune is operating .

  • Measures how much profit Altimmune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • An Operating Margin of -57,308.1% means the company generated $-573.08  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Altimmune Inc:

  • The MRQ is -57,308.1%. The company is operating very inefficient. -2
  • The TTM is -106,557.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-57,308.1%TTM-106,557.4%+49,249.3%
TTM-106,557.4%YOY-383,173.0%+276,615.5%
TTM-106,557.4%5Y-100,058.7%-6,498.8%
5Y-100,058.7%10Y-52,658.3%-47,400.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-57,308.1%-286.1%-57,022.0%
TTM-106,557.4%-224.4%-106,333.0%
YOY-383,173.0%-288.4%-382,884.6%
5Y-100,058.7%-475.2%-99,583.5%
10Y-52,658.3%-624.7%-52,033.6%
1.2.2. Operating Ratio

Measures how efficient Altimmune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 574.08 means that the operating costs are $574.08 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Altimmune Inc:

  • The MRQ is 574.081. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1,729.833. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ574.081TTM1,729.833-1,155.752
TTM1,729.833YOY6,366.350-4,636.516
TTM1,729.8335Y1,642.128+87.705
5Y1,642.12810Y870.021+772.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ574.0812.997+571.084
TTM1,729.8333.247+1,726.586
YOY6,366.3503.766+6,362.584
5Y1,642.1285.675+1,636.453
10Y870.0217.857+862.164

1.3. Liquidity of Altimmune Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Altimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 17.25 means the company has $17.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Altimmune Inc:

  • The MRQ is 17.255. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.136. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.255TTM14.136+3.119
TTM14.136YOY12.206+1.930
TTM14.1365Y15.313-1.178
5Y15.31310Y11.171+4.142
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.2553.930+13.325
TTM14.1364.251+9.885
YOY12.2065.436+6.770
5Y15.3136.045+9.268
10Y11.1716.363+4.808
1.3.2. Quick Ratio

Measures if Altimmune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Quick Ratio of 21.86 means the company can pay off $21.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Altimmune Inc:

  • The MRQ is 21.857. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.345. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.857TTM18.345+3.512
TTM18.345YOY15.045+3.300
TTM18.3455Y19.408-1.063
5Y19.40810Y14.347+5.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.8573.629+18.228
TTM18.3454.065+14.280
YOY15.0455.397+9.648
5Y19.4085.993+13.415
10Y14.3476.277+8.070

1.4. Solvency of Altimmune Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Altimmune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Altimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Altimmune assets are financed with 7.9% credit (debt) and the remaining percentage (100% - 7.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Altimmune Inc:

  • The MRQ is 0.079. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.091. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.079TTM0.091-0.013
TTM0.091YOY0.092-0.001
TTM0.0915Y0.112-0.021
5Y0.11210Y0.177-0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0790.332-0.253
TTM0.0910.334-0.243
YOY0.0920.268-0.176
5Y0.1120.366-0.254
10Y0.1770.390-0.213
1.4.2. Debt to Equity Ratio

Measures if Altimmune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.5% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Altimmune Inc:

  • The MRQ is 0.085. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.100. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.085TTM0.100-0.015
TTM0.100YOY0.102-0.001
TTM0.1005Y0.129-0.029
5Y0.12910Y0.461-0.332
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0850.381-0.296
TTM0.1000.390-0.290
YOY0.1020.334-0.232
5Y0.1290.434-0.305
10Y0.4610.466-0.005

2. Market Valuation of Altimmune Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Altimmune generates.

  • Above 15 is considered overpriced but always compare Altimmune to the Biotechnology industry mean.
  • A PE ratio of -6.30 means the investor is paying $-6.30 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Altimmune Inc:

  • The EOD is -3.859. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.302. Based on the earnings, the company is expensive. -2
  • The TTM is -4.038. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.859MRQ-6.302+2.442
MRQ-6.302TTM-4.038-2.264
TTM-4.038YOY-9.738+5.700
TTM-4.0385Y-9.683+5.645
5Y-9.68310Y-45.501+35.818
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.859-2.315-1.544
MRQ-6.302-2.560-3.742
TTM-4.038-2.664-1.374
YOY-9.738-4.122-5.616
5Y-9.683-6.258-3.425
10Y-45.501-6.108-39.393
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Altimmune Inc:

  • The EOD is -7.386. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.060. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.346. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.386MRQ-12.060+4.674
MRQ-12.060TTM-5.346-6.715
TTM-5.346YOY-13.041+7.696
TTM-5.3465Y-12.101+6.755
5Y-12.10110Y-41.602+29.502
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.386-3.067-4.319
MRQ-12.060-3.251-8.809
TTM-5.346-3.545-1.801
YOY-13.041-5.595-7.446
5Y-12.101-8.315-3.786
10Y-41.602-8.708-32.894
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Altimmune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.11 means the investor is paying $4.11 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Altimmune Inc:

  • The EOD is 2.517. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.109. Based on the equity, the company is fair priced.
  • The TTM is 2.153. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.517MRQ4.109-1.593
MRQ4.109TTM2.153+1.956
TTM2.153YOY4.327-2.175
TTM2.1535Y3.809-1.656
5Y3.80910Y26.766-22.957
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5171.905+0.612
MRQ4.1092.111+1.998
TTM2.1532.095+0.058
YOY4.3272.836+1.491
5Y3.8093.443+0.366
10Y26.7663.794+22.972
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Altimmune Inc.

3.1. Institutions holding Altimmune Inc

Institutions are holding 51.466% of the shares of Altimmune Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Ameriprise Financial Inc5.90120.01414183682417279138314.1218
2023-12-31BlackRock Inc5.70520.001240447072577916.8074
2023-12-31Vanguard Group Inc5.03840.000935719722276776.8079
2023-09-30TANG CAPITAL MANAGEMENT LLC3.8791.0089275000000
2023-12-31Nuveen Asset Management, LLC2.43640.00631727316-1719462-49.8861
2023-12-31Geode Capital Management, LLC1.68350.0014119352814019213.3093
2023-12-31Goldman Sachs Group Inc1.47890.00111048500926017756.0372
2023-12-31Morgan Stanley - Brokerage Accounts1.46820.0011040901556843115.0364
2023-12-31State Street Corporation1.4310.0006101454614366516.4965
2023-09-30LAURION CAPITAL MANAGEMENT LP1.14210.0128809685-1029919-55.9859
2023-12-31Timelo Investment Management Inc.1.14137.94518090957790952596.9833
2023-12-31Amvescap Plc.1.05250.0027461817131522159.1692
2023-12-31Susquehanna International Group, LLP1.03430.0016733254619488544.5282
2023-09-30D. E. Shaw & Co LP1.03070.00273073222649444.9181
2023-12-31JANE STREET GROUP, LLC0.81870.0017580444521495884.6545
2023-12-31Group One Trading, LP0.77220.0162547441380791228.4974
2023-12-31Northern Trust Corp0.66840.001473829234195.1995
2023-12-31Ardsley Advisory Partners0.4810.59341000-651050-65.6267
2023-12-31Ensign Peak Advisors Inc0.46090.007332677700
2023-12-31Fred Alger Management, LLC0.46080.01983266583266580
Total 38.08479.63527000248+6615137+24.5%

3.2. Funds holding Altimmune Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv3.09060.0013166053900
2024-01-31CT American Smaller Coms(US) InstAccGBP2.81311.2271511445-851208-36.0276
2024-02-29iShares Russell 2000 ETF2.40470.02511292026-211-0.0163
2024-01-31CT (Lux) American Smaller Com 9U USD2.02941.25941090353-463421-29.8255
2024-01-31CREF Stock R11.61610.00786833500
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47830.0094794277173402.2318
2024-01-31CREF Global Equities R11.22150.023565632300
2023-12-31Vanguard Strategic Small-Cap Equity Inv1.1580.476221949975619.0943
2023-12-31Fidelity Small Cap Index0.97820.0233525581406388.38
2024-02-01iShares Russell 2000 Value ETF0.94060.04235053486400.1268
2024-02-29Invesco Dorsey Wright SmallCap Momt ETF0.76560.5537411322103252.5748
2024-02-29Invesco Dorsey Wright Healthcare MomtETF0.60152.534532320400
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.5790.00931110000
2023-12-31Kennedy Extended Small Cap0.56680.21243045213045210
2024-01-31Fidelity Extended Market Index0.55210.007829664700
2024-02-29Eastern Shore Small Cap Equity0.42480.7391228240-1585-0.6897
2023-12-31Morgan Stanley Inst Inception I0.38260.50362055782055780
2023-12-31Morgan Stanley Inception0.38260.50772055782055780
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.37430.02582011001890010.3732
2024-02-29Vanguard Russell 2000 ETF0.35740.0244192011149528.4446
Total 22.71728.206312205722-398197-3.3%

3.3. Insider Transactions

Insiders are holding 0.776% of the shares of Altimmune Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-15David DrutzBUY3002.88

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Altimmune Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6160.031+1885%-0.049+108%0.103+500%0.066+836%
Book Value Per Share--2.7382.398+14%2.714+1%2.181+26%1.333+105%
Current Ratio--17.25514.136+22%12.206+41%15.313+13%11.171+54%
Debt To Asset Ratio--0.0790.091-14%0.092-15%0.112-30%0.177-56%
Debt To Equity Ratio--0.0850.100-15%0.102-16%0.129-34%0.461-82%
Dividend Per Share----0%-0%22.638-100%11.460-100%
Eps---0.446-0.312-30%-0.299-33%-0.240-46%-0.089-80%
Free Cash Flow Per Share---0.233-0.267+15%-0.221-5%-0.195-16%-0.042-82%
Free Cash Flow To Equity Per Share--0.7930.036+2094%-0.021+103%0.124+538%0.148+436%
Gross Profit Margin--1.0601.015+4%1.000+6%1.003+6%1.001+6%
Intrinsic Value_10Y_max---3.796--------
Intrinsic Value_10Y_min---10.130--------
Intrinsic Value_1Y_max---0.198--------
Intrinsic Value_1Y_min---1.074--------
Intrinsic Value_3Y_max---0.734--------
Intrinsic Value_3Y_min---3.194--------
Intrinsic Value_5Y_max---1.437--------
Intrinsic Value_5Y_min---5.264--------
Market Cap488468589.440-63%797572080.000382834598.400+108%833196966.240-4%569218331.584+40%751436966.128+6%
Net Profit Margin---855.162-1116.215+31%-3664.133+328%-980.540+15%-502.482-41%
Operating Margin---573.081-1065.574+86%-3831.730+569%-1000.587+75%-526.583-8%
Operating Ratio--574.0811729.833-67%6366.350-91%1642.128-65%870.021-34%
Pb Ratio2.517-63%4.1092.153+91%4.327-5%3.809+8%26.766-85%
Pe Ratio-3.859+39%-6.302-4.038-36%-9.738+55%-9.683+54%-45.501+622%
Price Per Share6.890-63%11.2505.400+108%11.753-4%8.029+40%10.599+6%
Price To Free Cash Flow Ratio-7.386+39%-12.060-5.346-56%-13.041+8%-12.101+0%-41.602+245%
Price To Total Gains Ratio11.177-63%18.250-3478.196+19158%20.680-12%-701.729+3945%-232.350+1373%
Quick Ratio--21.85718.345+19%15.045+45%19.408+13%14.347+52%
Return On Assets---0.150-0.115-23%-0.098-35%-0.119-21%-0.080-47%
Return On Equity---0.163-0.126-22%-0.108-34%-0.135-17%-0.014-91%
Total Gains Per Share--0.6160.031+1885%-0.049+108%22.741-97%11.526-95%
Usd Book Value--194099000.000169985500.000+14%192431250.000+1%154611170.400+26%94505306.375+105%
Usd Book Value Change Per Share--0.6160.031+1885%-0.049+108%0.103+500%0.066+836%
Usd Book Value Per Share--2.7382.398+14%2.714+1%2.181+26%1.333+105%
Usd Dividend Per Share----0%-0%22.638-100%11.460-100%
Usd Eps---0.446-0.312-30%-0.299-33%-0.240-46%-0.089-80%
Usd Free Cash Flow---16533000.000-18964250.000+15%-15678000.000-5%-13828751.600-16%-2958235.775-82%
Usd Free Cash Flow Per Share---0.233-0.267+15%-0.221-5%-0.195-16%-0.042-82%
Usd Free Cash Flow To Equity Per Share--0.7930.036+2094%-0.021+103%0.124+538%0.148+436%
Usd Market Cap488468589.440-63%797572080.000382834598.400+108%833196966.240-4%569218331.584+40%751436966.128+6%
Usd Price Per Share6.890-63%11.2505.400+108%11.753-4%8.029+40%10.599+6%
Usd Profit---31641000.000-21691000.000-31%-20730500.000-34%-17937587.450-43%-6679162.100-79%
Usd Revenue--37000.000106500.000-65%-17000.000+146%919392.250-96%1577692.950-98%
Usd Total Gains Per Share--0.6160.031+1885%-0.049+108%22.741-97%11.526-95%
 EOD+2 -6MRQTTM+26 -8YOY+20 -145Y+19 -1710Y+18 -18

4.2. Fundamental Score

Let's check the fundamental score of Altimmune Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.859
Price to Book Ratio (EOD)Between0-12.517
Net Profit Margin (MRQ)Greater than0-855.162
Operating Margin (MRQ)Greater than0-573.081
Quick Ratio (MRQ)Greater than121.857
Current Ratio (MRQ)Greater than117.255
Debt to Asset Ratio (MRQ)Less than10.079
Debt to Equity Ratio (MRQ)Less than10.085
Return on Equity (MRQ)Greater than0.15-0.163
Return on Assets (MRQ)Greater than0.05-0.150
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Altimmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.691
Ma 20Greater thanMa 508.586
Ma 50Greater thanMa 1009.557
Ma 100Greater thanMa 2009.054
OpenGreater thanClose6.970
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Reconciled Depreciation  -236-120-356-149-505-47-5522,4421,890
Total Other Income Expense Net 1,4342511,685-1,5721131,7561,869-12,306-10,437



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets210,640
Total Liabilities16,541
Total Stockholder Equity194,099
 As reported
Total Liabilities 16,541
Total Stockholder Equity+ 194,099
Total Assets = 210,640

Assets

Total Assets210,640
Total Current Assets209,526
Long-term Assets1,114
Total Current Assets
Cash And Cash Equivalents 135,158
Short-term Investments 62,698
Net Receivables 4,853
Other Current Assets 6,817
Total Current Assets  (as reported)209,526
Total Current Assets  (calculated)209,526
+/-0
Long-term Assets
Property Plant Equipment 1,014
Long-term Assets Other 100
Long-term Assets  (as reported)1,114
Long-term Assets  (calculated)1,114
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities12,143
Long-term Liabilities4,398
Total Stockholder Equity194,099
Total Current Liabilities
Short-term Debt 496
Accounts payable 2,070
Other Current Liabilities 9,577
Total Current Liabilities  (as reported)12,143
Total Current Liabilities  (calculated)12,143
+/- 0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt175
Long-term Liabilities Other 4,223
Long-term Liabilities  (as reported)4,398
Long-term Liabilities  (calculated)4,398
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -466,331
Accumulated Other Comprehensive Income -5,004
Other Stockholders Equity 665,427
Total Stockholder Equity (as reported)194,099
Total Stockholder Equity (calculated)194,099
+/-0
Other
Capital Stock7
Cash and Short Term Investments 197,856
Common Stock Shares Outstanding 58,443
Current Deferred Revenue0
Liabilities and Stockholders Equity 210,640
Net Debt -134,487
Net Invested Capital 194,099
Net Working Capital 197,483
Property Plant and Equipment Gross 2,626
Short Long Term Debt Total 671



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-30
> Total Assets 
202
69,722
70,087
70,497
70,740
71,164
71,739
71,739
19,400
72,493
66,611
62,223
53,756
50,305
56,391
53,724
43,021
41,970
34,065
28,482
23,864
21,615
27,199
23,875
26,316
21,640
22,804
24,754
23,808
23,411
22,741
21,972
24,587
20,619
17,139
14,374
15,223
23,350
21,978
25,465
22,616
20,896
19,862
18,735
27,931
140,539
224,739
20,728
90,842
74,346
63,030
63,030
52,102
52,861
54,751
54,751
61,976
56,388
54,058
54,233
102,544
232,995
245,115
264,251
257,261
236,907
218,865
205,660
209,906
225,277
206,928
187,083
183,316
166,573
210,640
210,640166,573183,316187,083206,928225,277209,906205,660218,865236,907257,261264,251245,115232,995102,54454,23354,05856,38861,97654,75154,75152,86152,10263,03063,03074,34690,84220,728224,739140,53927,93118,73519,86220,89622,61625,46521,97823,35015,22314,37417,13920,61924,58721,97222,74123,41123,80824,75422,80421,64026,31623,87527,19921,61523,86428,48234,06541,97043,02153,72456,39150,30553,75662,22366,61172,49319,40071,73971,73971,16470,74070,49770,08769,722202
   > Total Current Assets 
202
69,722
70,087
70,497
70,740
71,164
71,739
71,739
10,000
64,184
58,475
38,540
32,878
30,548
46,142
45,031
33,578
32,060
24,217
18,426
14,376
12,302
23,584
20,413
22,940
18,337
19,613
21,529
20,683
20,379
19,796
19,068
21,692
17,766
14,339
11,586
12,433
20,585
19,251
22,739
19,906
18,246
17,227
16,137
25,399
138,036
222,270
18,292
16,996
26,122
23,466
23,466
11,866
11,966
39,372
39,372
46,105
41,624
39,395
39,637
87,970
218,132
230,257
245,192
238,625
218,263
204,126
191,093
195,504
211,004
192,813
173,111
169,532
152,964
209,526
209,526152,964169,532173,111192,813211,004195,504191,093204,126218,263238,625245,192230,257218,13287,97039,63739,39541,62446,10539,37239,37211,96611,86623,46623,46626,12216,99618,292222,270138,03625,39916,13717,22718,24619,90622,73919,25120,58512,43311,58614,33917,76621,69219,06819,79620,37920,68321,52919,61318,33722,94020,41323,58412,30214,37618,42624,21732,06033,57845,03146,14230,54832,87838,54058,47564,18410,00071,73971,73971,16470,74070,49770,08769,722202
       Cash And Cash Equivalents 
6
1,471
1,398
1,323
1,003
764
675
675
7,100
60,337
40,583
19,239
14,152
10,141
19,752
17,245
9,273
4,188
2,674
735
682
2,718
11,785
9,708
14,161
10,406
11,237
15,304
11,777
14,726
12,702
12,873
15,790
15,943
10,481
9,535
11,265
19,620
18,643
15,725
18,412
17,389
15,570
14,236
23,158
69,107
153,995
15,782
8,368
17,117
8,769
8,769
4,171
7,964
33,719
33,719
41,672
10,972
8,963
11,275
64,742
143,495
115,918
149,932
174,102
174,864
190,301
179,947
135,858
127,465
111,097
104,690
102,352
86,855
135,158
135,15886,855102,352104,690111,097127,465135,858179,947190,301174,864174,102149,932115,918143,49564,74211,2758,96310,97241,67233,71933,7197,9644,1718,7698,76917,1178,36815,782153,99569,10723,15814,23615,57017,38918,41215,72518,64319,62011,2659,53510,48115,94315,79012,87312,70214,72611,77715,30411,23710,40614,1619,70811,7852,7186827352,6744,1889,27317,24519,75210,14114,15219,23940,58360,3377,1006756757641,0031,3231,3981,4716
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
12,154
6,416
4,813
3,107
3,191
6,774
6,178
7,382
3,137
3,137
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,842
66,811
66,811
34
34
3,534
3,534
592
34
0
0
0
28,226
28,277
21,644
15,484
63,283
100,006
76,575
43,724
25,021
0
0
48,898
74,362
73,783
61,039
57,602
53,924
62,698
62,69853,92457,60261,03973,78374,36248,8980025,02143,72476,575100,00663,28315,48421,64428,27728,226000345923,5343,534343466,81166,81166,84200000000000000000000000003,1373,1377,3826,1786,7743,1913,1074,8136,41612,1540000000000
       Net Receivables 
0
0
0
0
0
0
0
0
2,500
3,219
5,246
6,563
8,163
11,456
10,282
11,051
16,033
18,723
17,433
16,938
12,934
8,662
9,684
8,862
7,354
6,384
7,896
5,422
8,231
5,289
6,547
5,580
5,235
1,613
3,627
1,650
617
304
408
6,568
1,178
660
1,475
1,437
1,822
1,578
999
2,042
7,145
7,964
10,168
10,168
6,426
3,524
4,471
4,471
3,710
1,981
1,650
5,984
6,689
10,010
12,373
12,699
11,351
11,050
5,838
6,073
6,095
4,353
2,541
3,370
3,715
4,529
4,853
4,8534,5293,7153,3702,5414,3536,0956,0735,83811,05011,35112,69912,37310,0106,6895,9841,6501,9813,7104,4714,4713,5246,42610,16810,1687,9647,1452,0429991,5781,8221,4371,4756601,1786,5684083046171,6503,6271,6135,2355,5806,5475,2898,2315,4227,8966,3847,3548,8629,6848,66212,93416,93817,43318,72316,03311,05110,28211,4568,1636,5635,2463,2192,50000000000
       Other Current Assets 
196
68,251
68,689
69,175
69,738
70,400
0
122
400
68
16
254
16
5,844
12,917
9,961
2,095
1,766
973
752
760
922
1,000
1,029
1,425
1,547
480
802
675
364
547
614
668
210
231
401
551
661
199
446
316
196
182
464
419
510
465
468
1,449
1,007
4,529
4,529
677
444
1,183
1,183
723
444
504
733
1,055
1,343
1,961
5,985
9,447
7,329
13,397
5,073
4,653
4,824
5,358
3,978
5,822
7,615
6,817
6,8177,6155,8223,9785,3584,8244,6535,07313,3977,3299,4475,9851,9611,3431,0557335044447231,1831,1834446774,5294,5291,0071,4494684655104194641821963164461996615514012312106686145473646758024801,5471,4251,0291,0009227607529731,7662,0959,96112,9175,844162541668400122070,40069,73869,17568,68968,251196
   > Long-term Assets 
0
0
0
0
0
0
0
0
9,400
8,309
8,136
23,683
20,879
19,757
10,249
8,692
9,443
9,910
9,848
10,057
9,488
9,313
3,615
3,463
3,376
3,303
3,191
3,225
3,124
3,032
2,946
2,905
2,894
2,853
2,800
2,788
2,790
2,764
2,728
2,726
2,710
2,650
2,636
2,598
2,532
2,502
2,469
2,436
73,847
48,224
39,564
39,564
40,236
40,895
15,378
15,378
15,871
14,764
14,663
14,596
14,573
14,864
14,858
19,059
18,636
18,644
14,739
14,567
14,402
14,273
14,115
13,972
13,784
13,609
1,114
1,11413,60913,78413,97214,11514,27314,40214,56714,73918,64418,63619,05914,85814,86414,57314,59614,66314,76415,87115,37815,37840,89540,23639,56439,56448,22473,8472,4362,4692,5022,5322,5982,6362,6502,7102,7262,7282,7642,7902,7882,8002,8532,8942,9052,9463,0323,1243,2253,1913,3033,3763,4633,6159,3139,48810,0579,8489,9109,4438,69210,24919,75720,87923,6838,1368,3099,40000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
6,000
6,716
6,571
6,289
6,386
6,191
5,313
5,211
5,909
6,208
6,262
6,481
6,182
6,042
1,178
1,061
974
901
789
702
626
553
484
457
460
430
386
381
387
362
326
324
308
248
234
196
184
154
121
88
293
280
603
603
1,476
1,407
1,343
1,343
1,955
1,880
1,803
1,744
1,687
1,982
1,961
6,064
4,751
4,718
1,448
1,337
1,236
1,172
1,081
1,007
882
765
1,014
1,0147658821,0071,0811,1721,2361,3371,4484,7184,7516,0641,9611,9821,6871,7441,8031,8801,9551,3431,3431,4071,476603603280293881211541841962342483083243263623873813864304604574845536267027899019741,0611,1786,0426,1826,4816,2626,2085,9095,2115,3136,1916,3866,2896,5716,7166,00000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
2,308
2,503
2,503
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
2,348
35,399
9,335
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000009,33535,3992,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,3482,5032,5032,308000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
1,300
1,333
1,313
1,222
1,198
1,128
925
875
908
930
929
918
855
833
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
430
0
0
0
17,821
0
0
0
14,955
0
38,132
38,586
38,722
38,722
38,349
38,339
13,852
13,852
13,760
12,742
12,732
12,738
12,786
12,795
12,824
12,879
12,956
12,994
12,419
12,419
12,419
12,419
12,419
12,419
12,419
12,419
0
012,41912,41912,41912,41912,41912,41912,41912,41912,99412,95612,87912,82412,79512,78612,73812,73212,74213,76013,85213,85238,33938,34938,72238,72238,58638,132014,95500017,82100043000000000000000008338559189299309088759251,1281,1981,2221,3131,3331,30000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
175
150
131
0
0
0
0
0
0
0
0
22
0
0
0
1,972
0
0
0
22
0
73,553
47,944
38,961
225
411
1,149
184
170
156
142
129
115
101
87
977
115
929
932
74
61
46
682
19
0
0
1
0
010019682466174932929115977871011151291421561701841,14941122538,96147,94473,5530220001,9720002200000000131150175000000000000000000000000000
> Total Liabilities 
179
13,758
411
14,195
14,155
14,277
14,625
14,625
31,200
28,492
26,039
26,102
39,031
39,137
37,428
37,150
32,690
35,483
32,181
33,691
33,462
33,022
14,988
13,040
12,243
7,102
6,952
10,983
10,262
10,860
11,068
12,030
11,366
9,265
9,804
6,049
4,359
5,244
3,704
5,442
4,280
3,224
3,213
3,108
3,680
4,156
205,280
2,677
14,866
25,516
14,353
14,353
16,292
13,178
6,438
6,438
5,751
7,004
8,538
12,337
23,022
33,289
19,239
17,813
15,983
27,643
19,730
20,792
15,371
20,248
21,635
19,351
15,602
16,176
16,541
16,54116,17615,60219,35121,63520,24815,37120,79219,73027,64315,98317,81319,23933,28923,02212,3378,5387,0045,7516,4386,43813,17816,29214,35314,35325,51614,8662,677205,2804,1563,6803,1083,2133,2244,2805,4423,7045,2444,3596,0499,8049,26511,36612,03011,06810,86010,26210,9836,9527,10212,24313,04014,98833,02233,46233,69132,18135,48332,69037,15037,42839,13739,03126,10226,03928,49231,20014,62514,62514,27714,15514,19541113,758179
   > Total Current Liabilities 
179
179
411
617
576
698
1,046
1,046
18,100
10,813
8,997
9,731
15,418
29,439
35,873
33,761
31,217
16,330
13,466
14,380
12,691
30,033
6,163
6,702
5,929
3,692
4,615
5,314
5,659
6,971
7,488
7,788
7,722
5,413
6,796
3,465
2,831
3,885
2,582
4,537
3,335
2,381
2,179
2,640
3,269
3,728
204,838
2,235
5,528
4,180
3,840
3,840
7,067
8,345
4,527
4,527
3,480
2,467
3,923
6,045
4,917
6,294
12,020
9,824
9,096
19,127
18,276
19,124
13,845
15,742
17,054
14,951
11,437
11,871
12,143
12,14311,87111,43714,95117,05415,74213,84519,12418,27619,1279,0969,82412,0206,2944,9176,0453,9232,4673,4804,5274,5278,3457,0673,8403,8404,1805,5282,235204,8383,7283,2692,6402,1792,3813,3354,5372,5823,8852,8313,4656,7965,4137,7227,7887,4886,9715,6595,3144,6153,6925,9296,7026,16330,03312,69114,38013,46616,33031,21733,76135,87329,43915,4189,7318,99710,81318,1001,0461,046698576617411179179
       Short-term Debt 
175
106
0
0
83
83
0
91
11,800
4,000
4,000
4,000
4,000
16,933
17,378
17,777
17,256
0
0
0
0
20,058
0
0
0
0
0
1,053
455
1,890
2,081
2,329
2,168
1,000
2,092
1,000
1,000
993
746
498
249
2
16
468
799
1,151
1,465
0
50
50
50
50
1,311
1,467
72
72
410
358
259
266
905
328
357
366
375
402
411
421
431
442
452
463
474
485
496
49648547446345244243142141140237536635732890526625935841072721,4671,3115050505001,4651,1517994681622494987469931,0001,0002,0921,0002,1682,3292,0811,8904551,0530000020,058000017,25617,77717,37816,9334,0004,0004,0004,00011,800910838300106175
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
861
0
0
0
1,083
0
0
0
985
0
620
640
650
666
1,895
0
72
227
164
105
0
0
632
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000632001051642277201,89566665064062009850001,08300086100000000000000000000000000000000000000
       Accounts payable 
4
14
7
55
43
12
0
161
700
1,775
1,394
1,434
3,721
3,206
3,871
3,409
2,573
1,030
1,934
5,957
8,403
6,732
3,128
3,924
2,483
446
1,446
1,411
2,063
1,847
1,697
1,290
2,993
1,159
1,128
472
437
282
391
537
208
306
521
166
711
615
927
839
1,131
495
3,754
129
245
151
4,456
373
270
50
18
930
195
875
612
418
1,421
6
2,034
2,205
2,872
1,419
4,804
5,238
4,035
3,046
2,070
2,0703,0464,0355,2384,8041,4192,8722,2052,03461,42141861287519593018502703734,4561512451293,7544951,1318399276157111665213062085373912824374721,1281,1592,9931,2901,6971,8472,0631,4111,4464462,4833,9243,1286,7328,4035,9571,9341,0302,5733,4093,8713,2063,7211,4341,3941,77570016101243557144
       Other Current Liabilities 
0
10
404
562
98
132
0
203
5,600
5,038
618
4,297
7,697
9,300
14,625
378
69
15,300
11,532
8,423
4,288
3,243
3,035
2,778
3,447
3,246
3,170
2,850
3,142
3,234
2,329
3,294
2,054
2,782
3,234
1,931
0
2,553
249
122
183
2,075
1,658
2,474
2,558
3,114
203,911
1,395
4,315
3,616
36
3,641
5,478
6,707
195
4,063
2,768
2,039
3,584
4,802
3,783
5,071
11,032
9,020
7,242
18,699
6,090
16,498
10,542
13,881
11,798
9,250
7,402
8,825
9,577
9,5778,8257,4029,25011,79813,88110,54216,4986,09018,6997,2429,02011,0325,0713,7834,8023,5842,0392,7684,0631956,7075,4783,641363,6164,3151,395203,9113,1142,5582,4741,6582,0751831222492,55301,9313,2342,7822,0543,2942,3293,2343,1422,8503,1703,2463,4472,7783,0353,2434,2888,42311,53215,3006937814,6259,3007,6974,2976185,0385,600203013298562404100
   > Long-term Liabilities 
0
13,579
0
13,579
13,579
13,579
0
13,579
13,100
17,679
17,042
16,371
23,614
9,699
1,555
3,389
1,473
19,153
18,714
19,311
20,771
2,990
8,825
6,337
6,313
3,410
2,336
5,669
4,603
3,890
3,579
4,242
3,644
3,852
3,008
2,583
1,528
1,359
1,122
905
944
843
1,034
468
412
427
443
443
9,338
21,335
10,513
10,513
9,226
4,834
1,911
1,911
2,271
4,537
4,615
6,291
18,105
26,996
7,218
7,989
6,887
8,516
1,454
1,668
1,526
4,506
4,581
4,400
4,165
4,305
4,398
4,3984,3054,1654,4004,5814,5061,5261,6681,4548,5166,8877,9897,21826,99618,1056,2914,6154,5372,2711,9111,9114,8349,22610,51310,51321,3359,3384434434274124681,0348439449051,1221,3591,5282,5833,0083,8523,6444,2423,5793,8904,6035,6692,3363,4106,3136,3378,8252,99020,77119,31118,71419,1531,4733,3891,5559,69923,61416,37117,04217,67913,10013,579013,57913,57913,579013,5790
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,235
1,984
1,764
1,704
1,460
1,218
974
730
485
240
0
0
0
0
0
0
0
0
0
0
0
617
4,618
4,575
3,776
4,285
1,942
1,852
2,317
2,212
1,787
1,865
1,791
1,715
1,926
1,828
1,719
1,617
1,566
1,454
1,668
1,526
4,506
0
4,400
4,165
0
0
004,1654,40004,5061,5261,6681,4541,5661,6171,7191,8281,9261,7151,7911,8651,7872,2122,3171,8521,9424,2853,7764,5754,618617000000000002404857309741,2181,4601,7041,7641,9842,235000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,238
9,282
5,955
510
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000005105,9559,2828,2380000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
258
0
0
0
229
0
0
0
196
443
223
4,196
3,974
8,600
8,132
4,289
1,409
359
400
2,985
3,130
4,875
16,760
25,435
7,218
7,989
6,887
8,516
331
652
622
4,506
3,909
0
3,736
4,002
0
04,0023,73603,9094,5066226523318,5166,8877,9897,21825,43516,7604,8753,1302,9854003591,4094,2898,1328,6003,9744,19622344319600022900025800000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,313
3,410
2,336
2,878
2,055
1,546
1,296
2,201
1,849
2,286
1,689
1,496
715
852
629
420
482
228
492
0
0
0
0
0
8,720
8,479
5,938
5,440
4,431
2,892
59
59
59
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000005959592,8924,4315,4405,9388,4798,720000004922284824206298527151,4961,6892,2861,8492,2011,2961,5462,0552,8782,3363,4106,313000000000000000000000000
> Total Stockholder Equity
23
55,964
69,676
56,302
56,586
56,887
0
57,114
-11,800
44,001
40,572
36,121
14,725
11,168
18,963
16,574
10,331
6,487
1,884
-5,208
-9,597
-11,408
12,211
10,835
14,073
14,538
15,852
13,771
13,545
12,551
11,674
9,943
13,220
11,354
7,336
8,325
10,865
18,106
18,274
20,023
18,336
17,672
16,649
15,626
24,251
136,383
19,459
18,051
75,977
48,830
39,396
48,678
35,810
39,683
48,313
48,313
56,225
49,384
45,520
41,897
79,522
199,706
225,876
246,437
241,278
209,264
199,135
184,868
194,535
205,029
185,293
167,732
167,714
150,397
194,099
194,099150,397167,714167,732185,293205,029194,535184,868199,135209,264241,278246,437225,876199,70679,52241,89745,52049,38456,22548,31348,31339,68335,81048,67839,39648,83075,97718,05119,459136,38324,25115,62616,64917,67218,33620,02318,27418,10610,8658,3257,33611,35413,2209,94311,67412,55113,54513,77115,85214,53814,07310,83512,211-11,408-9,597-5,2081,8846,48710,33116,57418,96311,16814,72536,12140,57244,001-11,80057,114056,88756,58656,30269,67655,96423
   Common Stock
0
1
1
1
1
1
0
1
0
2
2
2
2
2
3
3
3
3
3
3
3
3
5
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
7
7
7
2
2
2
2
4
0
1
1
1
2
2
2
3
3
4
4
4
4
4
4
5
5
5
5
5
5
7
755555544444433222111042222777666666666555555555555553333333322222010111110
   Retained Earnings 
-3
144
277
482
766
1,067
1,294
1,294
-81,300
-82,303
-87,403
-92,420
-114,273
-118,616
-123,818
-129,831
-136,676
-150,639
-156,311
-164,255
-170,648
-174,976
-189,892
-191,968
-194,405
-194,439
-193,689
-196,369
-197,126
-197,340
-198,610
-200,721
-201,957
-205,903
-210,328
-212,586
-213,025
-217,654
-220,283
-218,820
-221,161
-222,486
-223,724
-224,951
-216,906
-107,671
-29,870
-32,067
-38,949
-68,854
-77,685
-77,685
-89,997
-92,348
-116,856
-116,856
-122,340
-133,279
-137,376
-141,262
-158,029
-175,799
-186,421
-210,945
-235,771
-269,282
-293,171
-312,601
-332,708
-356,224
-377,884
-397,958
-414,019
-434,690
-466,331
-466,331-434,690-414,019-397,958-377,884-356,224-332,708-312,601-293,171-269,282-235,771-210,945-186,421-175,799-158,029-141,262-137,376-133,279-122,340-116,856-116,856-92,348-89,997-77,685-77,685-68,854-38,949-32,067-29,870-107,671-216,906-224,951-223,724-222,486-221,161-218,820-220,283-217,654-213,025-212,586-210,328-205,903-201,957-200,721-198,610-197,340-197,126-196,369-193,689-194,439-194,405-191,968-189,892-174,976-170,648-164,255-156,311-150,639-136,676-129,831-123,818-118,616-114,273-92,420-87,403-82,303-81,3001,2941,2941,067766482277144-3
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
207,232
207,810
208,526
209,111
209,663
210,102
210,496
210,878
215,393
217,472
217,877
221,126
224,105
235,980
238,781
239,065
239,490
240,151
240,367
240,571
241,151
244,035
49,323
50,112
120,662
122,393
121,656
125,358
130,844
137,072
170,208
183,314
183,604
187,683
187,915
188,209
242,580
380,544
417,338
462,418
482,084
483,582
497,342
502,505
532,398
566,551
0
570,786
586,908
0
0
00586,908570,7860566,551532,398502,505497,342483,582482,084462,418417,338380,544242,580188,209187,915187,683183,604183,314170,208137,072130,844125,358121,656122,393120,66250,11249,323244,035241,151240,571240,367240,151239,490239,065238,781235,980224,105221,126217,877217,472215,393210,878210,496210,102209,663209,111208,526207,810207,232000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
25
55,819
69,398
55,819
55,819
55,819
0
55,819
67,900
52,495
126,491
127,278
127,797
128,706
142,392
146,663
147,396
156,243
157,004
157,674
159,998
162,437
200,847
201,571
207,232
207,810
208,526
209,111
209,663
210,102
210,496
210,878
215,393
217,472
217,877
221,126
224,105
235,980
238,781
239,065
239,490
240,151
242,224
240,571
241,151
244,035
49,323
50,112
120,662
114,154
-4,577
121,656
130,334
137,072
-5,040
170,208
183,604
187,683
187,915
188,209
242,580
380,544
417,338
462,418
482,084
483,582
497,342
502,505
532,398
566,551
568,399
570,786
586,908
590,206
665,427
665,427590,206586,908570,786568,399566,551532,398502,505497,342483,582482,084462,418417,338380,544242,580188,209187,915187,683183,604170,208-5,040137,072130,334121,656-4,577114,154120,66250,11249,323244,035241,151240,571242,224240,151239,490239,065238,781235,980224,105221,126217,877217,472215,393210,878210,496210,102209,663209,111208,526207,810207,232201,571200,847162,437159,998157,674157,004156,243147,396146,663142,392128,706127,797127,278126,49152,49567,90055,819055,81955,81955,81969,39855,81925



Balance Sheet

Currency in USD. All numbers in thousands.